Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
Sci Immunol. 2024 Feb 2;9(92):eadg7995. doi: 10.1126/sciimmunol.adg7995. Epub 2024 Feb 2.
Sci Immunol. 2024.
PMID: 38306416
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
García M, Moreno R, Gil-Martin M, Cascallò M, de Olza MO, Cuadra C, Piulats JM, Navarro V, Domenech M, Alemany R, Salazar R.
García M, et al. Among authors: de olza mo.
Hum Gene Ther. 2019 Mar;30(3):352-364. doi: 10.1089/hum.2018.107. Epub 2018 Nov 13.
Hum Gene Ther. 2019.
PMID: 30234393
Clinical Trial.
Item in Clipboard
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.
Petrylak DP, et al. Among authors: de olza mo.
Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3.
Lancet Oncol. 2015.
PMID: 25743937
Clinical Trial.
Item in Clipboard
The utility of ancillary tests in monitoring cutaneous melanoma patients to detect visceral metastasis.
Ferreres JR, Marcoval J, Fodge K, de Olza MO, Viñals A, Fabra A.
Ferreres JR, et al. Among authors: de olza mo.
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2493-5. doi: 10.1111/jdv.12602. Epub 2014 Jul 25.
J Eur Acad Dermatol Venereol. 2015.
PMID: 25059751
No abstract available.
Item in Clipboard
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR.
Pernas S, et al. Among authors: de olza mo.
Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8.
Breast Cancer Res Treat. 2012.
PMID: 22772380
Clinical Trial.
Item in Clipboard
Cite
Cite